-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 10, Deyuan Pharmaceutical, a company listed on the Beijing Stock Exchange, issued an announcement stating that the company's acarbose tablets, which were reported as imitations of Category 4, were batch-produced and deemed to have been reviewed
.
Acarbose Tablets is an α-glucosidase inhibitor.
In 2020, the total terminal sales of Chinese public medical institutions and Chinese urban physical pharmacies will exceed 5 billion yuan
The original research company of acarbose tablets is Bayer of Germany, which was first listed in Germany in 1990 and approved for listing in China in 1994
.
As an α-glucosidase inhibitor, Acarbose Tablets can effectively reduce blood sugar by binding with small intestinal mucosal epithelial cells, competitively inhibiting the activity level of α-glucosidase, delaying or inhibiting the conversion of amylase into glucose
.
According to data from Minet.
com, in 2020, the total sales of acarbose in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and China's urban physical pharmacy terminals will exceed 5 billion yuan.
The best-selling oral hypoglycemic drug in China
.
Acarbose products currently on the market in China include Acarbose Tablets, Acarbose Capsules, and Acarbose Chewable Tablets
.
Acarbose tablets are the target of domestic pharmaceutical companies keen to imitate.
In the past two years, a total of 9 local companies have been approved to produce this variety, and there are already 12 manufacturers
Deyuan Pharmaceutical passed/deemed to pass the consistency evaluation of drugs
Source: MED2.
As a pharmaceutical manufacturing enterprise focusing on the field of endocrine therapy drugs, Deyuan Pharmaceutical currently has 9 products that have passed/deemed to pass the consistency evaluation, including 7 diabetes drugs, Metformin Hydrochloride Sustained-Release Tablets, Nateglinide Tablets, Four varieties including pioglitazone hydrochloride tablets and pioglitazone metformin tablets were the first to review
Data source: Minet database, company announcement
